InsidersTradesSigma
PREDILIFE Stock: price and directors' dealings · France · AMF
Track the PREDILIFE share price and the full directors' dealings record of the company, a listed equity based in France. Shares trade on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, PREDILIFE has recorded 73 public disclosures. Market capitalisation: €9.2m. The latest transaction was reported on 6 July 2026 (Acquisition). Among the most active insiders: Stéphane RAGUSA. All data is free.
73
Insider Decl.
0
Thresholds
€599,147
55 ops.
Buy Volume
€710,200
6 ops.
Sell Volume
55Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 6 July 2026
Declarations73 total
265 shares@ €2.310.0067% mcap17.1% of flowActionEuronext Growth Paris2026DD1124853
Ideal exit: 28 Mar 2027 (T+270)
65 shares@ €2.400.0016% mcap100.0% of flowActionEuronext Growth Paris2026DD1123873
Ideal exit: 21 Mar 2027 (T+270)
10 shares@ €2.500.0003% mcap0.2% of flowActionEuronext Growth Paris2026DD1122772
Ideal exit: 15 Mar 2027 (T+270)
240 shares@ €2.660.0062% mcap6.1% of flowActionEuronext Growth Paris2026DD1121514
Ideal exit: 7 Mar 2027 (T+270)
165 shares@ €2.450.0039% mcap13.6% of flowActionEuronext Growth Paris2026DD1120450
Ideal exit: 5 Mar 2027 (T+270)
1,000 shares@ €2.500.026% mcap97.5% of flowActionEuronext Growth Paris2026DD1119616
Ideal exit: 1 Mar 2027 (T+270)
235 shares@ €2.550.0062% mcap6.1% of flowActionEuronext Growth Paris2026DD1119617
Ideal exit: 2 Mar 2027 (T+270)
310 shares@ €2.830.0086% mcap9.5% of flowActionEuronext Growth Paris2026DD1119264
Ideal exit: 27 Feb 2027 (T+270)
780 shares@ €2.3540.018% mcap19.8% of flowActionEuronext Growth Paris2026DD1119265
Ideal exit: 28 Feb 2027 (T+270)
2,045 shares@ €3.04660.055% mcap94.9% of flowActionEuronext Growth Paris2026DD1110958
Ideal exit: 24 Jan 2027 (T+270)
110 shares@ €3.06730.0030% mcap5.1% of flowActionEuronext Growth Paris2026DD1109222
Ideal exit: 12 Jan 2027 (T+270)
20 shares@ €3.140.0006% mcap100.0% of flowActionEuronext Growth Paris2026DD1107455
Ideal exit: 5 Jan 2027 (T+270)
300 shares@ €4.800.1% of flowActionEuronext Growth Paris2025DD1038359
Ideal exit: 10 Feb 2026 (T+270)
500 shares@ €4.800.2% of flowActionEuronext Growth Paris2025DD1038297
Ideal exit: 10 Feb 2026 (T+270)
5,000 shares@ €3.80100.0% of flowActionEuronext Growth Paris2025DD1025542
2,000 shares@ €3.820.5% of flowActionEuronext Growth Paris2025DD1019754
2,000 shares@ €3.820.5% of flowActionEuronext Growth Paris2025DD1019341
400 shares@ €3.900.1% of flowActionEuronext Growth Paris2025DD1017947
Ideal exit: 27 Oct 2025 (T+270)
250 shares@ €4.000.1% of flowActionEuronext Growth Paris2025DD1017084
Ideal exit: 21 Oct 2025 (T+270)
500 shares@ €4.000.1% of flowActionEuronext Growth Paris2025DD1015061
Ideal exit: 7 Oct 2025 (T+270)
1,000 shares@ €3.800.3% of flowActionEuronext Growth Paris2025DD1013574
7,000 shares@ €3.801.9% of flowActionEuronext Growth Paris2024DD1012244
5,000 shares@ €4.201.5% of flowActionEuronext Growth Paris2024DD1007164
1,000 shares@ €3.800.3% of flowActionEuronext Growth Paris2024DD1005161
Ideal exit: 8 Aug 2025 (T+270)
500 shares@ €3.700.1% of flowActionEuronext Growth Paris2024DD1003167
Ideal exit: 26 Jul 2025 (T+270)
25 of 73 declarations
About PREDILIFE
PREDILIFE is a French company specializing in predictive medicine, listed on Euronext Growth Paris under ISIN code FR0010169920 and ticker ALPRE. Founded in 2004, the company was built around a clear mission: to make personalized prevention more accessible by combining artificial intelligence, Big Data and clinically validated medical methods. Its positioning sits at the intersection of healthcare, diagnostics and disease prevention, with a strong technology component. The company’s history is rooted in a long research and development cycle. After roughly 14 years of R&D, PREDILIFE obtained medical device certification and launched its first predictive health check-ups in France and internationally. Its flagship product, MammoRisk®, was developed to assess breast cancer risk using reference clinical databases and advanced statistical models. This product helped establish PREDILIFE as a pioneer in personalized prevention, particularly in oncology. Since 2021, the company has expanded its predictive portfolio to cover several other major conditions, including prostate cancer, melanoma, colorectal cancer, lung cancer and cardiovascular disease. This diversification strengthens the company’s value proposition: offering predictive tests that can identify significant health risks earlier, thereby improving prevention, screening and medical follow-up. PREDILIFE also markets predictive check-ups for companies, helping HR teams and occupational health departments structure prevention initiatives for employees. From a market standpoint, PREDILIFE operates in a specialized niche within digital health and medical prevention. Its model addresses a market that is still relatively early-stage and not fully standardized, but one that offers meaningful growth potential as employers, healthcare providers and institutions seek more targeted screening solutions. The company highlights partnerships with major international databases and with recognized healthcare institutions in France and Europe. Its geographic footprint remains primarily centered on France, while its offering is designed for broader international expansion. Notable features of PREDILIFE include its science-driven model, which combines medical research, algorithms and individualized prevention. The company also emphasizes the economic rationale of its predictive check-ups, which are presented as significantly less expensive than traditional comprehensive medical screenings. Overall, PREDILIFE stands out as an innovative healthcare company with a strong blend of scientific credibility, technological depth and scalable prevention-oriented solutions.
